A 57-year-old man with 5 different squamous cell carcinoma  by Galdeano Rubio, M. et al.
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S198–S207
Available online at www.sciencedirect.com
journa l homepage: ht tp : / /www.e lsev ier .com/ locate / rpor
Clinical cases MIR: Long survivors in oncology
A case of long-term survival in woman with breast cancer
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Background. Substantial changes have been seen in cancer mortality rates over the past two decades, speciﬁcally breast cancer
which is the leading cause of new cancer diagnosis, it’s average decline in death rates over 2% per year since 1990, which is the
combined result of earlier diagnosis and better treatment. A cancer survivor by theNational Cancer Institute’s ofﬁcial deﬁnition is
any patient who has been diagnosed with cancer. A long-term cancer survivor is someone who has lived past the risk of primary
cancer recurrence or who has a long-term chronic malignancy. Case presentation: We describe a 61 year-old female patient who
was diagnosed in 1994 with Stage IIB (pT2pN1M0) inﬁltrating ductal carcinoma of the left breast; she was treated on February of
1994 with breast conserving therapy (lumpectomy and surgical axillary staging+QT (adriamicina+CMF×8c) +RDT). In February
of 1997 she presented bone metastases with clinical presentation of clavicle fracture. After that she was treated with multiple
chemotherapies andpalliative radiotherapy schemes (seven times ondifferent anatomical localizations) due to bone, biochemical
and visceral progression; in January of 2012 she presented osteonecrosis in left jaw due to long-term bisphosphonates. Currently
she has a karnofsky performance status of 80%, and is being treated with docetaxel with excellent response.
Conclusion. There is constant progress in breast cancer treatment, so it’s expected that in the upcoming decade it should lead to
continued decreases inmortality rates, increasing the cancer survivorship and the clinical challenges that entails. The knowledge
of the needs of long-term cancer survivors is critical to delivery of ongoing care that maximizes the beneﬁts of treatment,
minimizing and properly managing late toxicities and enhancing their quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.148
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Ninety percent of Head and neck cancer (H&NC) are squamous cell carcinoma (SCC). The use of tobacco is associated with an
increased risk of H&NC. Due to improvements in therapy and therefore the consequent increase in overall survival in patients
with H&NC, it is not uncommon to develop secondary neoplasms (particularly if toxic habits continue) such as other primary
H&HC, esophageal cancer (SCC is associated with tobacco, alcohol, or prior history of Head and Neck cancers) or lung cancers
(caused by carcinogens and tumor promoters inhaled via cigarette smoking) We report a 57 year-old-man with alcoholic habit of
6 drink units daily (previously 9–10) and former smoker of two packs a day (currently 10 cigarettes/day) with glomerulonephritis
secondary to leukocytoclastic vasculitis whose cancer history includes: SCC of the oropharynx T2N0 treated in June 2007 by
uvulopalatoplasty and bilateral neck dissection. Currently free of disease. SCC of tongue in 2009 treated by partial glossectomy
and right posterior cordectomy. Currently free of disease. Diagnosed in June 2011 of a synchronous SCC of the right pyriform sinus,
esophageal inﬁltrating SCC and lung adenocarcinoma, T3N1M0 and T1N0M0 respectively. Pyriform sinus tumor and esophageal
carcinoma were both treated with concurrent chemoradiation (CBDCA+5-FU-RDT plus 70Gy 2Gy/fr) with complete response by
PET/CT and EUS respectively. Lung lesion was treated by SBRT 60Gy in 8 fractions at 7.5Gy/fr. PET/CT in October 2012 objectived
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local relapse of lung tumor. Patient underwent lobectomy. The patient has currently a good performance status and is free of
disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.149
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Breast cancer is the most common cause of cancer in women, accounting for about a third of all cancer in women. It is the most
frequently diagnosed cancer in women, primarily due to utilization of screening mammography programs. Breast cancer ranks
the second place among cancer deaths in women. In recent years, directly related to the progress of antineoplastic therapy and
earlier detection,mortality frombreast cancer has begun to decrease substantially in developed countries.We report a 81 year-old
Woman diagnosed in 1996 of a left breast neoplasia as a case of a multitreated long survivor breast cancer patient. The patient
was initially treated with lumpectomy and lymphadenectomy resulting in inﬁltrative ductal carcinoma with carcinomatous
lymphangitis and massive nodal metastasis pT4N2Mx. Completing adjuvant radiotherapy (50+20Gy) and subsequent tamoxifen
from 1996 to 2002. In 2009 bone metastases were diagnosed by scintigraphy and minimum pulmonary metastasis. Femara and
Zometa were administered. In September 2010, bone scintigraphy showed bone progression. Aromasil was prescribed. Posterior
latercervical tumor diagnosed in April 2011. Change to Faslodex. Treated with RDT (50 Gy) in November 2011 with good response.
In January 2012 CT scan evidenced multiple adenopathic tumors and two new tumor mass in right gluteus region. 4 cycles
of capecitabine were administered with secondary G3 palm-plantar disease. CT scan post-capecitabine in June 2012 showed
stable disease. In July 2012 multiple subcutaneous tumors, the biggest, in right inguinal fossa were diagnosed. Tamoxifen and
pamidronate were prescribed. In January 2013 the patient was assessed by the Radiation Oncology Department to treat right
inguinal subcutaneous bleeding tumor who ﬁnally planned 60Gy at 2Gy/fr. The radiotherapy started on 07/02/2013 with good
tolerance.
http://dx.doi.org/10.1016/j.rpor.2013.03.150
Breast cancer. A chronic disease?
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71 year old woman, previously healthy, she was diagnosed in 1992 CDI right breast, grade 1, T1 N0 M0, (AP CDI 0.5 cm grade 1
with free edges and intense intraductal component) treated with lumpectomy plus axillary clearance (18 lymph nodes without
tumor), adjuvant RT (with classical fractionation) and hormone therapy. She has continuing periodic checks in this service. In July
2009, being asymptomatic, showed elevated tumor marker CA 15.3 and was diagnosed with bone dissemination (scintigraphy:
is the pathological accumulation of radioactive material in skullcap, thoracic spine, ﬁfth left anterior rib and right scapula) PET
demonstrated an injury in D11 and, pathological uptake in the descending colon that later it was made a Colonoscopy showing
diverticula in the sigmoid. In February of 2012, was made treatment RT, in the injury, D11 DT 30Gy and with good tolerance
to the treatment. The patient started aromatase inhibitor therapy and, zoledronic acid from then until now, with good clinical.
Currently the patient is completely asymptomatic with ECOG 100%. Why this case is interesting? It is about a patient with a
20-years follow up and an active normal life, the highlights in this case are a long evolution of a breast cancer that subsequently
showed bone metastases and a demonstration of how one could have a chronic illness and still maintain a good quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.151
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Male, 25 years old Oncological history: When he was 6 years old, after headache and vomiting episodes, a brain TC is performed
in 03/17/94 and it ﬁndings are a posterior fossa tumor with secondary hidrocephaly for which was completely surgically removed
with a PA compatible with meduloblastoma. Complicated therefrom with meningitis which left him with important neurological
sequels that improved progressively. In control cranial CT 27/06/94 nodular area is half goal in the ﬂoor of the fourth ventricle
tumor relative to rest. Oncological treatment RTE-2D with Cobalt 60 by means of two lateral ﬁelds that encompass all the craneal
volume. Simultaneously the neuroaxis is radiated by means of a direct posterior ﬁeld, with a total dose of 4.000 cGy to all
volumes with an overprint in the posterior fossa until reaching a total dose of 5.500 cGy (5×180 cGy). During the treatment, and
after presenting with neurological worsening, an IRM is performed in which it is obvious a relapse in the neuroaxis of T11-L1
which required the administration of a dose of overprinting in that area until reaching a dosage of 4.500 cGy. Tretament duration
from 08/01/94 to 09/15/94. Presented good tolerance. Evolution: He remains in follow ups persisting with neurological symptoms.
